Apellis Pharmaceuticals

$46.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.10 (+2.44%) As of 3:36 PM UTC today

Why Robinhood?

You can buy or sell APLS and other stocks, options, and ETFs commission-free!

About APLS

Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. The listed name for APLS is Apellis Pharmaceuticals, Inc. Common Stock.

CEO

Cedric Francois

Employees

235

Headquarters

Waltham, Massachusetts

Founded

2009

Market Cap

3.65B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

507.83K

High Today

$48.34

Low Today

$45.44

Open Price

$45.93

Volume

74.02K

52 Week High

$58.47

52 Week Low

$16.85

Analyst Ratings

87%

of 15 ratings

Buy

87%

Hold

13%

Sell

APLS Earnings

-$2.29

-$1.22

-$0.14

$0.93

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

$0.93 per share

Replay Earnings Call